Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Outcome of Immune Checkpoint Inhibitors. (3rd July 2019)

• Record Type: Journal Article
• Authors: Xie, Xianhe; Liu, Junjin; Yang, Haitao; Chen, Huijuan; Zhou, Sijing; Lin, Heng; Liao, Ziyuan; Ding, Yin; Ling, Liting; Wang, Xuewen
• Is Part Of: Cancer investigation. Volume 37:Number 6(2019)
• Page Start: 265
• Page End: 274
• Publication Date: 2019-07-03
• Subjects: Melanoma -- non-small cell lung cancer (NSCLC) -- metastatic renal cell carcinoma (mRCC) -- immune checkpoint inhibitors (ICI) -- neutrophil-to-lymphocyte ratio (NLR); Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.1080/07357907.2019.1639057
• Languages: English
• ISSNs: 0735-7907

Abstract

Abstract: A meta-analysis of 14 studies (16 cohorts) incorporating 1751 participants was performed to evaluate the correlation between baseline neutrophil-to-lymphocyte ratio (NLR) and outcome of immune checkpoint inhibitors (ICI). The pooled hazard ratio (HR) suggested elevated pretreatment NLR was associated with poor OS ( HR: 2.61, 95% confidence intervals (CI): 1.77–3.86, p < 0.00001) and PFS ( HR: 1.74, 95% CI : 1.34–2.27, p < 0.0001). Stratified analyses on tumor types, ICI agents, the cutoff value of NLR and study regions exhibited the similar outcomes. This study demonstrated that elevated NLR was a predictor of poor OS and PFS for ICI.